Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)

Basit Öğe Kaydı
dc.authorid0000-0001-9636-4113
dc.contributor.authorSevindik, Ömür Gökmen
dc.contributor.authorGemici, Aliihsan
dc.contributor.authorUsta, Furkan Selim
dc.contributor.authorÇakır, Aslı
dc.contributor.authorSadri, Sevil
dc.contributor.authorBekoz, Hüseyin
dc.contributor.authorSargın, Fatma Deniz
dc.date.accessioned2022-04-05T09:39:38Z
dc.date.available2022-04-05T09:39:38Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.description.abstractGemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. Despite growing evidence regarding its efficacy and safety among AML patients there is limited data about the use of GO in isolated extra-medullary relapsed AML. Extramedullary AML remains as an unmet clinical need regarding the poor prognosis and lack of a standard therapeutic approach. Our cases demonstrated a rapid and long lasting response with a favorable toxicity profile, in patients who were treated with GO as a single agent after an isolated extramedullary relapsing disease.
dc.identifier.citationSevindik, Ö. G., Gemici, A., Usta, F. S., Çakır, A., Sadri, S., Bekoz, H. ... Sargın, F. D. (2019). Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO). 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). Orlando Florida, December 7-10, 2019. https://dx.doi.org/10.1182/blood-2019-126195
dc.identifier.doi10.1182/blood-2019-126195
dc.identifier.issn0006-4971
dc.identifier.issn1528-0020
dc.identifier.issueSupplement:1
dc.identifier.urihttps://dx.doi.org/10.1182/blood-2019-126195
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9218
dc.identifier.volume134
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.institutionauthorSevindik, Ömür Gökmen
dc.institutionauthorGemici, Aliihsan
dc.institutionauthorUsta, Furkan Selim
dc.institutionauthorÇakır, Aslı
dc.institutionauthorBekoz, Hüseyin
dc.institutionauthorSargın, Fatma Deniz
dc.language.isoen
dc.publisherThe American Society of Hematology
dc.relation.ispartof61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcute Myeloid Leukemia (AML)
dc.subjectGemtuzumab Ozogamycin (GO)
dc.subjectStem Cell Transplantation
dc.titleAdult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Sevindik-Omur-2019.pdf
Boyut:
87.09 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu